Herbal Formula Ma-Zi-Ren-Wan (MZRW) on Bowel Movement Function and Gut Microbiome Among Cancer Survivors With Constipation: A Double-blinded Randomized Controlled Trial (RELIEVE)

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to find out whether MZRW is an effective treatment for constipation in cancer survivors. The researchers will compare MZRW with placebo, a pill that looks like MZRW and is given in the same way, but contains no medication. The researchers will also study the effect MZRW has on the gut microbiome. The gut microbiome is a diverse community of microorganisms living in the digestive system, essential for digestion and immune function.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or greater;

• A diagnosis of cancer with no restrictions placed on type of cancer or stage;

• Completed surgery, chemotherapy, immunotherapy, and/or radiotherapy, or an investigational therapy at least one month prior to study initiation. Patients on stable doses of hormone therapy or targeted therapies will not be excluded;

• Karnofsky functional score of ≥ 60;

• Cancer survivors who have met the Rome IV criteria (Table 3) of the symptoms of functional constipation which must include two or more of the following:

‣ Straining more than 25% of defecations.

⁃ Lumpy or hard stools (7-point Bristol stool scale 1 or 2) more than 25% of defecations.

⁃ Sensation of incomplete evacuation more than one-fourth (25%) of defecations.

⁃ Sensation of anorectal obstruction/blockage more than one-fourth (25%) of defecations.

⁃ Manual maneuvers to facilitate more than one-fourth (25%) of defecations.

⁃ Fewer than three spontaneous bowel movements per week.

⁃ Loose stools are rarely present without the use of laxatives.

⁃ Insufficient criteria for irritable bowel syndrome.

• Patient should be able to understand and complete all study assessments on their own

• Patient should be able to understand and provide signed informed consent in English.

∙ Table 3. Rome IV criteria for functional constipation FUNCTIONAL CONSTIPATION Diagnostic criteria\*

⁃ Must include two or more of the following:\*\*

⁃ Straining during more than ¼ (25%) of defecations

⁃ Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations

⁃ Sensation of incomplete evacuation more than ¼ (25%) of defecations

⁃ Sensation of anorectal obstruction/blockage more than ¼ (25%) of defecations

⁃ Fewer than three SBM per week

⁃ Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor)

⁃ Loose stools are rarely present without the use of laxatives

‣ Insufficient criteria for irritable bowel syndrome Note \*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

Locations
United States
New Jersey
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITING
Basking Ridge
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITING
Middletown
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITING
Montvale
New York
Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)
RECRUITING
Commack
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITING
Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING
New York
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITING
Rockville Centre
Contact Information
Primary
Jun Mao, MD, MSCE
maoj@mskcc.org
646-608-8552
Backup
Yen Nien (Jason) Hou, PharmD
houy@mskcc.org
646-608-8555
Time Frame
Start Date: 2025-07-15
Estimated Completion Date: 2028-07-15
Participants
Target number of participants: 70
Treatments
Experimental: MZRW
Participants will receive 2 weeks of MZRW
No_intervention: Placebo
Participants will receive 2 weeks of placebo
Related Therapeutic Areas
Sponsors
Leads: Memorial Sloan Kettering Cancer Center

This content was sourced from clinicaltrials.gov